Meningococcal group A, C, W 135 and Y conjugate vaccine(GlaxoSmithKline Plc)(Meningococcal group A, C, W 135 and Y conjugate vaccine(GlaxoSmithKline Plc))

概要

基本信息

药物类型

预防性疫苗、类毒素疫苗、结合疫苗

别名

MenACWY、MenACWY conjugated vaccine、MenACWY-TT

+ [6]

靶点-

作用方式

刺激剂

作用机制

免疫刺激剂

治疗领域

在研适应症

非在研适应症

原研机构

在研机构

Pfizer Europe MA EEIG

非在研机构

GSK Plc

Pfizer Inc.

最高研发阶段批准上市

首次获批日期

欧盟 (2012-04-20),

脑膜炎球菌感染

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

54

项与 Meningococcal group A, C, W 135 and Y conjugate vaccine(GlaxoSmithKline Plc) 相关的临床试验

NCT05873751

/ CompletedN/A

Effect of Trumenba on Gonococcal Infections in Adolescents and Young Adults in the United States: a Retrospective Cohort Study

Brief Summary:
The main purpose of the study is to learn about how well Trumenba vaccine shot works against gonorrhea infection.
This study looks at data records from a database in the United States.
This study includes patient's data from the database who:
* Are 15-30 years old.
* Have received at least one dose of Trumenba and a MenACWY vaccine or who have received only MenACWY vaccine.
This data has already been collected in the past and is being studied between April and June of 2023.

开始日期2023-04-24

申办/合作机构

Pfizer Inc.

NCT04819113

/ Completed临床3期

A PHASE 3B, OPEN-LABEL, STUDY TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF NIMENRIX(Registered) IN HEALTHY INFANTS, GIVEN AT 3 AND 12 MONTHS OF AGE

This study will evaluate the safety and immunogenicity of a single dose of Nimenrix in infants at 3 months of age, followed by a second dose at 12 months of age. Current posology allows for 2 doses of Nimenrix before 6 months of age, where the first dose is administered from 6 weeks onwards with a second dose at least 2 months later, with a booster at 12 months; and in infants from 6 months of age, a single dose at 6 months, with a booster dose at 12 months. This study will provide valuable immunogenicity and safety data for a single dose in healthy infants <6 months of age, followed by the booster at 12 months

开始日期2021-04-09

申办/合作机构

Pfizer Inc.

NCT04645966

/ Terminated临床2期

A PHASE 2b TRIAL TO ASSESS THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF MenABCWY IN HEALTHY INFANTS 2 AND 6 MONTHS OF AGE

The aim of the study is to describe the safety, tolerability, and immunogenicity of MenABCWY in healthy infants 2 and 6 months of age.

开始日期2020-11-26

申办/合作机构

Pfizer Inc.

100 项与 Meningococcal group A, C, W 135 and Y conjugate vaccine(GlaxoSmithKline Plc) 相关的临床结果

登录后查看更多信息

100 项与 Meningococcal group A, C, W 135 and Y conjugate vaccine(GlaxoSmithKline Plc) 相关的转化医学

登录后查看更多信息

100 项与 Meningococcal group A, C, W 135 and Y conjugate vaccine(GlaxoSmithKline Plc) 相关的专利（医药）

登录后查看更多信息

267

项与 Meningococcal group A, C, W 135 and Y conjugate vaccine(GlaxoSmithKline Plc) 相关的文献（医药）

2025-12-31·Human Vaccines & Immunotherapeutics

Safety, tolerability, and immunogenicity of pentavalent meningococcal MenABCWY vaccine in healthy infants: A phase 2b randomized clinical trial

Article

作者: Salamanca de la Cueva, Ignacio ; Natalini Martinez, Silvina ; O’Neill, Robert ; Liberator, Paul A. ; Jodar, Luis ; Martinon-Torres, Federico ; Zolotas, Lefteris ; Gruber, William C. ; Lamberth, Erik ; Beeslaar, Johannes ; Anderson, Annaliesa S. ; Oladipupo, Islamiat ; Peyrani, Paula ; Trammel, James ; Maguire, Jason D.

Invasive meningococcal disease is an uncommon but serious disease predominantly affecting children. This phase 2b study evaluated MenABCWY in 6-month-old infants followed by MenB-fHbp and MenABCWY in 2-month-old infants, the latter being the target age and intervention. Participants were randomized to MenABCWY, 60 µg or 120 µg MenB-fHbp+MenACWY-TT, or 4CMenB+MenACWY-TT, administered as 2 primary and 1 booster dose. The primary safety objective was to describe the safety profile of MenABCWY in participants enrolled at 2 months. Primary immunogenicity objectives were the percentage of participants achieving seroprotective serum bactericidal antibody using human complement titers. Overall, 314 and 12 participants were randomized to sentinel cohort and open-label expanded-enrollment stages, respectively. Based on 2 reports of fever requiring invasive investigations and accompanied by cerebrospinal fluid pleocytosis and 1 report arising from a previous study, the Sponsor terminated the study. Local reactions and systemic events after primary vaccination were generally mild to moderate, and tended to be higher with MenABCWY versus 4CMenB+MenACWY-TT. Immunogenicity data suggest that 1 month after vaccination 2, MenABCWY responses for MenA/C/W/Y were robust and comparable with 4CMenB+MenACWY-TT in 2-month-old participants. Immune responses for MenB test strains were higher with MenABCWY versus 4CMenB+MenACWY-TT and generally similar with 60 µg and 120 µg MenB-fHbp+MenACWY-TT or MenABCWY. Based on the limited results, the consistency of MenB immune responses with 60 µg and 120 µg MenB-fHbp suggests doses < 60 µg could be investigated to assess whether a more acceptable safety profile in conjunction with beneficial immune responses is possible in 2-month-old infants.

2025-03-01·PHARMACOECONOMICS

Public Health Impact of Introducing a Pentavalent Vaccine Against Invasive Meningococcal Disease in the United States

Article

作者: Carrico, Justin ; Hicks, Katherine A ; Shah, Hiral Anil ; Grace, Mei ; Jutlla, Ginita ; Graham, Jonathan ; Kocaata, Zeki ; Herrera-Restrepo, Oscar ; Clements, Diana E ; Begum, Shahina ; Kuylen, Elise ; Burman, Cindy ; Sohn, Woo-Yun

BACKGROUND:

Invasive meningococcal disease (IMD) is primarily associated with five Neisseria meningitidis serogroups: A, B, C, W, or Y. In the United States (US), available vaccines protect against serogroups B (MenB), A, C, W, and Y (MenACWY), and A, B, C, W, and Y (MenABCWY). The Advisory Committee on Immunization Practices is re-evaluating the adolescent meningococcal vaccination schedule with varying recommendation formats. This analysis aimed to predict which schedule could avert the most IMD cases and have the most positive public health impact (PHI).

METHODS:

An epidemiological model compared the 15-year PHI of vaccination schedules using MenB, MenACWY, and/or MenABCWY vaccines versus current US standard of care (SoC). Varying coverage rates reflected routine, shared clinical decision making, and risk-based recommendations. Sensitivity analyses assessed robustness of the results to different inputs/assumptions.

RESULTS:

The most positive PHI compared with SoC was observed with one dose of MenACWY at 11 years of age and two doses of MenABCWY (6 months apart) at 16 years of age, assuming routine recommendation and coverage reflecting real-world uptake of MenACWY. This strategy resulted in 123 IMD cases averted (MenB: 59, MenACWY: 64), 17 deaths prevented, 574 life-years saved, and 757 quality-adjusted life-years gained versus SoC. Eliminating MenACWY vaccination at 11 years was found to result in an additional IMD burden.

CONCLUSION:

A routinely recommended two-dose pentavalent vaccine, with doses administered 6 months apart at 16 years of age, alongside the routinely recommended MenACWY vaccine at 11 years of age, would improve the PHI and benefits of IMD vaccination to society.

2025-02-01·Infectious Diseases and Therapy

A Phase 3B, Open-Label Study to Evaluate the Immunogenicity and Safety of the Quadrivalent Meningococcal Nimenrix® Vaccine When Given to Healthy Infants at 3 and 12 Months of Age

Article

作者: Jodar, Luis ; Findlow, Jamie ; Maansson, Roger ; Koski, Susanna ; Cutler, Mark ; Balmer, Paul ; Peyrani, Paula ; Anderson, Annaliesa S ; Martinon-Torres, Federico ; Zolotas, Lefteris ; Newton, Ryan ; Gruber, William C ; Beeslaar, Johannes ; Rämet, Mika

INTRODUCTION:

Infants and young children typically have the highest age-related risk of invasive meningococcal disease. The immunogenicity and safety of a single primary dose and a booster of a meningococcal A/C/W/Y tetanus toxoid conjugate vaccine (MenACWY-TT; Nimenrix^®) in infants were evaluated.

METHODS:

In this phase 3b, open-label, single-arm study, healthy 3-month-old infants received a single Nimenrix dose followed by a booster at age 12 months (1 + 1 series). Functional antibodies before and 1 month after each vaccination were evaluated with serum bactericidal antibody assays using rabbit (rSBA) or human (hSBA) complement for each A/C/W/Y serogroup. Primary endpoints were rSBA seroprotection (titers ≥ 1:8) rates and geometric mean titers (GMTs); supportive secondary endpoints included hSBA seroprotection (titers ≥ 1:4) rates and GMTs. Local reactions and systemic events occurring within 7 days, adverse events (AEs), serious AEs, and newly diagnosed chronic medical conditions following vaccination were assessed.

RESULTS:

Overall, 147 and 143 participants received the primary and booster Nimenrix doses, respectively. rSBA seroprotection rates across serogroups were 82.3-91.1% at 1 month after the primary dose and increased to 100% at 1 month after the booster. rSBA GMTs were considerably higher after the booster (1299.5‒2714.1) than after the primary dose (54.7‒202.4). In hSBA evaluations performed as supportive to rSBA evaluations, seroprotection rates increased from 38.8 to 95.5% after the primary dose to 100% after the booster, with corresponding GMT increases (8.8‒149.8 to 1208.4‒7299.6). Local reactions and most systemic events were mild to moderate in severity; no new safety concerns were identified.

CONCLUSION:

Nimenrix given at ages 3 and 12 months had a favorable safety profile and elicited protective immune responses and robust anamnestic booster responses across A/C/W/Y serogroups. These results provide important support for this alternative Nimenrix 1 + 1 immunization schedule for infants < 6 months, allowing flexibility in infant meningococcal immunization.

TRIAL REGISTRATION:

ClinicalTrials.gov, NCT04819113.

60

项与 Meningococcal group A, C, W 135 and Y conjugate vaccine(GlaxoSmithKline Plc) 相关的新闻（医药）

2025-02-19

·Delonix Bioworks

Penmenvy获批上市，脑膜炎疫苗进入五价时代

近日，GSK宣布其五价脑膜炎球菌疫苗Penmenvy（MenABCWY）获得美国FDA批准上市，适用于10~25岁人群。这款“五合一”疫苗针对脑膜炎球菌中最常见的A、B、C、W和Y五大血清群，可广泛覆盖五种最常见的引起侵袭性脑膜炎球菌病 (IMD) 的细菌，减少注射次数，简化免疫接种。来源：GSK官网全球脑膜炎疫苗市场进入五价时代侵袭性脑膜炎球菌病（IMD）是一种罕见但极为严重的疾病，可在24小时内夺去患者生命，即便幸存，也可能面临脑损伤、截肢、听力丧失等长期后果。此前，人们都是分开接种的B群脑膜炎球菌疫苗（MenB）和ACWY四价脑膜炎球菌疫苗（MenACWY）。其中，MenACWY疫苗在全球已有多个上市产品，而MenB疫苗仅有辉瑞的Trumenba和GSK的Bexsero。这种现状使得五价脑膜炎球菌疫苗（MenABCWY）的开发更具战略意义，它能够将多种血清群的保护力整合于一体，减少接种次数，简化免疫计划，从而大幅提升疫苗覆盖率。 Penmenvy的获批基于两项3期临床试验，结果显示其在免疫原性方面不劣于GSK的四价脑膜炎球菌疫苗（A、C、Y和W群）以及两剂B群脑膜炎球菌疫苗Bexsero。此外，该疫苗显示出良好的耐受性，其安全性与上述两种疫苗一致。Penmenvy将GSK的两种成熟疫苗的抗原成分结合，减少了注射次数，简化了免疫接种计划，有望提高疫苗覆盖率。此前，Penmenvy入选了业内知名机构科睿唯安（Clarivate）发布的Drugs to Watch报告，被认为有望在五年内成为重磅新药，并预测到2030年其在美国和欧盟市场的销售额可达9.05亿美元。除GSK的Penmenvy外，全球范围内还有辉瑞的五价脑膜炎球菌疫苗Penbraya于2023年10月获批上市，全球已进入五价脑膜炎疫苗时代。 B群脑膜炎疫苗：五价疫苗的成败关键由于技术门槛更高，B群脑膜炎球菌疫苗一直被认为是五价脑膜炎球菌疫苗成败的关键。GSK和辉瑞的五价疫苗的成功上市，很大程度上得益于其在B群脑膜炎球菌疫苗领域的深厚积累。目前，全球现有上市B群脑膜炎球菌疫苗仅有辉瑞的Trumenba和GSK的Bexsero。辉瑞的Trumenba采用重组蛋白技术，但由于其适应症人群年龄限制（仅适用于10~25岁），上市以来营收增长缓慢，2023年销售额约为1.26亿美元。相比之下，GSK的Bexsero凭借更广泛的适用人群（2个月以上），市场潜力得到充分释放，2024年销售额突破12.9亿美元，成为全球第七大畅销疫苗。 Bexsero的成功不仅体现了B群脑膜炎疫苗的市场价值，也凸显了其在五价疫苗开发中的关键作用。GSK和辉瑞正是基于其在B群脑膜炎疫苗领域的技术积累和市场经验，进一步开发了MenABCWY五价疫苗，极大地提升了疫苗的综合价值。随着全球脑膜炎球菌疫苗市场进入五价时代，B群脑膜炎疫苗的战略地位愈发重要，其不仅是五价疫苗的核心组成部分，更是推动疫苗市场增长的关键驱动力。羽冠生物：B群脑膜炎疫苗的中国创新力量作为中国创新细菌疫苗研发的领先企业，羽冠生物一直致力于B群脑膜炎疫苗的研发工作。针对传统OMV疫苗的技术瓶颈，羽冠生物推出了下一代工程化平台OMV Plus，实现了OMV的增效、增产和工艺简化。基于该平台研发的B群脑膜炎球菌OMV疫苗，在临床前数据中展现出成为该品类最优疫苗的潜力，并将在今年申报IND。我们欢迎国内外同行企业与羽冠生物洽谈合作，共同推动多价脑膜炎球菌疫苗的研发与上市，为中国乃至全球公众健康筑起坚固防线。如需合作洽谈，可以在公众号后台给我们留言或者发邮件到BD@delonixbio.com。关于羽冠生物羽冠生物是一家专注创新疫苗研发的合成生物学公司，总部位于上海张江。公司拥有超过10种关键病原菌的基因编辑改造能力，在病原菌基因元件数量以及编辑效率上均为国内领先，并在多糖、类毒素、细菌外囊泡(OMV)等关键疫苗组分的工程化改造上拥有丰富经验。公司已成功推出了三大独创技术平台，包括针对细菌外囊泡疫苗开发的OMV Plus技术平台、全菌疫苗开发的ProBVax技术平台以及组分疫苗开发的BioDVax技术平台，并拥有多个自主研发的创新细菌疫苗管线。自2021年成立以来，羽冠生物已荣获勃林格殷格翰创新大赛冠军， Venture50“新芽榜TOP50”， BSA“最具投资价值瞪羚企业”等奖项。更多信息，请访问https://delonixbio.com/

上市批准临床3期疫苗

2025-02-18

·drugs

FDA Approves More Broadly Protective Meningococcal Vaccine

TUESDAY, Feb. 18, 2025 -- The U.S. Food and Drug Administration has approved Penmenvy (Meningococcal Groups A, B, C, W, and Y Vaccine) for active immunization against invasive meningococcal disease (IMD), according to a press release from GlaxoSmithKline (GSK). Penmenvy, approved for use in individuals aged 10 through 25 years, targets five major serogroups of Neisseria meningitidis (A, B, C, W, and Y), the common cause of IMD. The vaccine is an injectable suspension for intramuscular use that combines components of GSK's two well-established meningococcal vaccines, Bexsero and Menveo. The vaccine's safety, tolerability, and immune response were supported by two phase 3 trials with more than 4,800 participants aged 10 to 25 years. The safety profile was found to be consistent with GSK's licensed meningococcal vaccines. The most common side effects reported were pain at the injection site, fatigue, headache, muscle pain, and nausea. "The consequences of IMD can be devastating for those who contract it, for their families and friends," Judy Klein, president and founder of Unity Consortium, a nonprofit organization focused on adolescent health and immunization in the United States, said in a statement. "We welcome new tools to help protect more adolescents from meningococcal disease. Pentavalent MenABCWY vaccines could help address the disease by providing protection against the five vaccine-preventable serogroups in one vaccine and making it easier for adolescents to get the coverage they need." Approval of Penmenvy was granted to GSK. More Information Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

上市批准临床3期疫苗临床结果

2025-02-18

·drugs

FDA Approves More Broadly Protective Meningococcal Vaccine, Penmenvy

TUESDAY, Feb. 18, 2025 -- The U.S. Food and Drug Administration has approved Penmenvy (Meningococcal Groups A, B, C, W, and Y Vaccine) for active immunization against invasive meningococcal disease (IMD), according to a press release from GlaxoSmithKline (GSK). Penmenvy, approved for use in individuals aged 10 through 25 years, targets five major serogroups of Neisseria meningitidis (A, B, C, W, and Y), the common cause of IMD. The vaccine is an injectable suspension for intramuscular use that combines components of GSK's two well-established meningococcal vaccines, Bexsero and Menveo. The vaccine's safety, tolerability, and immune response were supported by two phase 3 trials with more than 4,800 participants aged 10 to 25 years. The safety profile was found to be consistent with GSK's licensed meningococcal vaccines. The most common side effects reported were pain at the injection site, fatigue, headache, muscle pain, and nausea. "The consequences of IMD can be devastating for those who contract it, for their families and friends," Judy Klein, president and founder of Unity Consortium, a nonprofit organization focused on adolescent health and immunization in the United States, said in a statement. "We welcome new tools to help protect more adolescents from meningococcal disease. Pentavalent MenABCWY vaccines could help address the disease by providing protection against the five vaccine-preventable serogroups in one vaccine and making it easier for adolescents to get the coverage they need." Approval of Penmenvy was granted to GSK. More Information Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

上市批准临床3期疫苗临床结果

100 项与 Meningococcal group A, C, W 135 and Y conjugate vaccine(GlaxoSmithKline Plc) 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	Meningococcal group A, C, W 135 and Y conjugate vaccine(GlaxoSmithKline Plc)	J07AH08	-

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
脑膜炎球菌感染	欧盟	Pfizer Europe MA EEIG	2012-04-20
脑膜炎球菌感染	冰岛	Pfizer Europe MA EEIG	2012-04-20
脑膜炎球菌感染	列支敦士登	Pfizer Europe MA EEIG	2012-04-20
脑膜炎球菌感染	挪威	Pfizer Europe MA EEIG	2012-04-20

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
白喉	临床3期	菲律宾	GSK Plc	2005-06-16
白喉	临床3期	泰国	GSK Plc	2005-06-16
嗜血杆菌感染	临床3期	菲律宾	GSK Plc	2005-06-16
嗜血杆菌感染	临床3期	泰国	GSK Plc	2005-06-16
乙型肝炎	临床3期	菲律宾	GSK Plc	2005-06-16
乙型肝炎	临床3期	泰国	GSK Plc	2005-06-16
破伤风	临床3期	菲律宾	GSK Plc	2005-06-16
破伤风	临床3期	泰国	GSK Plc	2005-06-16
百日咳	临床3期	菲律宾	GSK Plc	2005-06-16
百日咳	临床3期	泰国	GSK Plc	2005-06-16

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04819113 (CTgov)	临床3期	脑膜炎球菌感染	149	Nimenrix	網衊繭觸夢鬱繭網鹹糧 = 顧鏇繭艱齋憲製構願醖簾鏇範襯築鑰願網獵壓 (膚繭艱範範醖鑰壓網獵, 夢糧範築鹹廠積壓範鹹 ~ 窪遞醖顧製製獵製窪糧) 更多	-	2024-03-18
NCT01939158 (CTgov)	临床3期	脑膜炎球菌感染	803	Meningococcal vaccine GSK134612 (ACWY1d Group)	獵壓膚艱憲膚蓋製鏇廠 = 顧鹹鹹選積憲鹽膚鹹鹹顧淵繭膚艱構積觸蓋鑰 (餘築願淵衊鬱鏇構範獵, 憲蓋鹹憲獵糧艱繭繭醖 ~ 構選範積鹹觸繭積衊選) 更多	-	2021-10-05
				Meningococcal vaccine GSK134612 (ACWY2d Group)	獵壓膚艱憲膚蓋製鏇廠 = 醖淵夢餘蓋網衊餘顧艱顧淵繭膚艱構積觸蓋鑰 (餘築願淵衊鬱鏇構範獵, 鏇網構膚艱蓋窪製蓋鬱 ~ 淵繭獵築構餘齋積淵糧) 更多
NCT03189745 (CTgov)	临床3期	脑膜炎球菌感染	229	MenACWY-TT vaccine (ACWY-TT Group)	鑰鑰積願鹹餘廠憲簾窪 = 鹹積網鬱蓋蓋淵簾蓋鑰簾壓鏇窪齋觸艱艱壓製 (範餘顧襯醖餘憲觸廠選, 鏇範網築壓獵糧範憲鹹 ~ 簾製製夢窪淵鏇鹹獵餘) 更多	-	2020-10-12
				MencevaxACWY vaccine+MenACWY-TT vaccine (MenPS Group)	鑰鑰積願鹹餘廠憲簾窪 = 築觸構窪壓網窪觸廠憲簾壓鏇窪齋觸艱艱壓製 (範餘顧襯醖餘憲觸廠選, 壓鑰繭艱鹹鹽觸選膚淵 ~ 顧鏇窪衊鹽淵遞鹽窪構) 更多
NCT01934140 (CTgov)	临床3期	脑膜炎球菌感染	311	Meningococcal vaccine GSK134612 (ACWY-TT Group)	遞顧顧簾鏇遞鹹製鏇蓋 = 齋糧鏇糧糧窪觸顧構願鏇繭願窪壓餘憲獵獵選 (積糧積觸鹹艱餘膚網選, 齋窪糧觸憲選繭夢鹹憲 ~ 獵積蓋鹽鏇鬱鏇淵鑰窪) 更多	-	2019-08-28
				Meningococcal vaccine GSK134612 (MenPS Group)	遞顧顧簾鏇遞鹹製鏇蓋 = 簾製鬱範鑰積網築鏇淵鏇繭願窪壓餘憲獵獵選 (積糧積觸鹹艱餘膚網選, 鹽憲襯鹹簾願網鬱築鬱 ~ 顧襯膚膚鹹糧鹽淵網艱) 更多
NCT01340898 (CTgov)	临床3期	脑膜炎球菌感染	753	SynflorixTM+Meningococcal vaccine GSK 134612+Infanrix-IPV (Nimenrix 3+1 Group)	築願觸蓋顧顧襯觸餘築 = 積衊壓製願網獵鹹淵繭鏇廠夢壓顧齋糧鑰壓製 (願窪衊鹽願鹽築鹹壓顧, 製艱襯觸選選窪窪鏇鹽 ~ 範醖構憲積窪構齋餘窪) 更多	-	2019-08-06
				SynflorixTM+Meningococcal vaccine GSK 134612+Infanrix-IPV (Nimenrix 1+1 Group)	願壓構鬱製膚鬱淵糧齋 = 膚窪糧構艱壓鑰艱構願鹹鬱簾構膚選鬱襯願膚 (積壓遞糧艱衊製遞構艱, 齋淵襯餘糧艱網選範夢 ~ 糧鹹選遞簾鏇築夢衊衊) 更多
NCT02446691 (CTgov)	临床4期	脑膜炎球菌感染	128	MenACWY	餘積範醖積簾襯觸壓醖 = 蓋鹹鏇鏇蓋選窪鏇簾憲範襯願顧範壓齋製鹽膚 (築窪獵壓築顧艱艱選鑰, 網鬱鹽構製衊餘顧繭構 ~ 憲獵膚選齋醖廠齋廠衊) 更多	-	2019-04-01
NCT01144663 (CTgov)	临床3期	脑膜炎球菌感染	2,095	Synflorix™+Nimenrix™+Infanrix™ hexa (Nimenrix 3 Group)	範衊鹹憲醖夢願鑰鹹餘 = 選鏇製顧積積顧鏇鑰糧積鏇蓋觸夢壓壓夢憲繭 (鑰蓋艱積鑰淵蓋願繭選, 齋簾選蓋製鑰膚遞構繭 ~ 鏇鹹選鏇餘衊淵積觸襯) 更多	-	2019-02-01
				Synflorix™+Nimenrix™+Infanrix™ hexa (Nimenrix 2 Group)	範衊鹹憲醖夢願鑰鹹餘 = 鬱簾廠鑰壓選鹹構襯簾積鏇蓋觸夢壓壓夢憲繭 (鑰蓋艱積鑰淵蓋願繭選, 窪願窪鏇遞鏇憲願構簾 ~ 夢鏇醖範積獵廠鬱積襯) 更多
NCT01266993 (CTgov)	临床3期	脑膜炎球菌感染	271	Nimenrix (Nimenrix Group)	鹽蓋簾觸製膚艱構築範 = 蓋獵壓淵簾鏇築衊膚築顧鏇蓋糧艱獵鹹簾築憲 (觸築壓築艱鑰網醖醖夢, 遞觸積築簾窪衊鹽獵鏇 ~ 簾廠衊夢繭鹽構顧鑰襯) 更多	-	2019-01-31
				Menjugate (Menjugate Group)	鹽蓋簾觸製膚艱構築範 = 廠簾鬱夢構觸觸願積淵顧鏇蓋糧艱獵鹹簾築憲 (觸築壓築艱鑰網醖醖夢, 膚窪蓋廠夢製鏇夢膚齋 ~ 顧齋觸廠鏇齋遞窪觸鹽) 更多
NCT01777308 (CTgov)	临床3期	脑膜炎球菌感染	156	Meningococcal conjugate vaccine GSK134612 (Menitorix Group)	選構壓憲鬱網襯窪製鏇 = 鏇廠選遞齋願廠構糧衊廠衊餘獵構築鏇衊夢簾 (夢顧積繭製製鑰襯醖艱, 襯廠鑰餘鑰窪構製鏇獵 ~ 壓襯衊鑰獵餘網構淵襯) 更多	-	2019-01-25
				Meningococcal conjugate vaccine GSK134612 (Meningitec + Hiberix Group)	選構壓憲鬱網襯窪製鏇 = 淵構糧鏇鬱鹽簾繭鬱顧廠衊餘獵構築鏇衊夢簾 (夢顧積繭製製鑰襯醖艱, 獵願遞遞簾製憲簾膚餘 ~ 壓蓋觸襯構選襯淵願鏇) 更多
NCT00508261 (CTgov)	临床3期	脑膜炎球菌感染	793	Nimenrix+Infanrix-hexa (Nimenrix + Infanrix-hexa Group)	餘憲糧蓋鹹壓衊積膚築 = 簾壓選襯鏇壓觸獵獵網鏇範網鏇製窪鹹糧觸壓 (憲遞衊鑰窪衊蓋廠範鹽, 網鏇網獵範憲鹽願製蓋 ~ 窪膚醖齋獵夢廠選鑰鬱) 更多	-	2019-01-24
				Infanrix-hexa™ vaccine+Nimenrix™ vaccine (Nimenrix Group)	餘憲糧蓋鹹壓衊積膚築 = 糧遞築淵鑰壓壓夢廠簾鏇範網鏇製窪鹹糧觸壓 (憲遞衊鑰窪衊蓋廠範鹽, 餘簾鹹願積願壓鏇鹽壓 ~ 鹽衊醖壓壓積醖製簾簾) 更多